Vitamin C deficiency aggravates tumor necrosis factor α-induced insulin resistance

Eur J Pharmacol. 2018 Jun 15:829:1-11. doi: 10.1016/j.ejphar.2018.03.044. Epub 2018 Apr 3.

Abstract

Chronic low-grade inflammation plays a major role in the development of insulin resistance. The potential role and underlying mechanism of vitamin C, an antioxidant and anti-inflammatory agent, was investigated in tumor necrosis factor-α (TNF-α)-induced insulin resistance. Gulonolactone oxidase knockout (Gulo-/-) mice genetically unable to synthesize vitamin C were used to induce insulin resistance by continuously pumping small doses of TNF-α for seven days, and human liver hepatocellular carcinoma cells (HepG2 cells) were used to induce insulin resistance by treatment with TNF-α. Vitamin C deficiency aggravated TNF-α-induced insulin resistance in Gulo-/- mice, resulting in worse glucose tolerance test (GTT) results, higher fasting plasma insulin level, and the inactivation of the protein kinase B (AKT)/glycogen synthase kinase-3β (GSK3β) pathway in the liver. Vitamin C deficiency also worsened liver lipid accumulation and inflammation in TNF-α-treated Gulo-/- mice. In HepG2 cells, vitamin C reversed the TNF-α-induced reduction of glucose uptake and glycogen synthesis, which were mediated by increasing GLUT2 levels and the activation of the insulin receptor substrate (IRS-1)/AKT/GSK3β pathway. Furthermore, vitamin C inhibited the TNF-α-induced activation of not only the mitogen-activated protein kinase (MAPKs), but also nuclear factor-kappa B (NF-κB) signaling. Taken together, vitamin C is essential for preventing and improving insulin resistance, and the supplementing with vitamin C may be an effective therapeutic intervention for metabolic disorders.

Keywords: Hepatocytes; Inflammatory cytokine; Insulin resistance; Vitamin C.

MeSH terms

  • Animals
  • Ascorbic Acid / pharmacology
  • Ascorbic Acid Deficiency / metabolism*
  • Ascorbic Acid Deficiency / pathology
  • Enzyme Activation / drug effects
  • Gene Expression Regulation / drug effects
  • Glucose / metabolism
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Hep G2 Cells
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • I-kappa B Kinase / metabolism
  • Insulin Resistance*
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Mice
  • NF-KappaB Inhibitor alpha / metabolism
  • NF-kappa B / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Vascular Endothelial Growth Factor A / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • NF-kappa B
  • Tumor Necrosis Factor-alpha
  • Vascular Endothelial Growth Factor A
  • NF-KappaB Inhibitor alpha
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • I-kappa B Kinase
  • JNK Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Glucose
  • Ascorbic Acid